Abstract: The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): or a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
February 5, 2019
Assignee:
RHYTHM PHARMACEUTICALS, INC.
Inventors:
Shubh Sharma, Leonardus H. T. Van Der Ploeg, Bart Henderson
Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.
Abstract: The present invention is directed to an amphipathic peptide and methods of using the amphipathic peptide for delivering small molecule agents to a cell. Ideally, the amphipathic cell penetrating peptide comprises less than approximately 50 amino acid residues with at least 6 arginine residues, at least 12 Alanine Residues, at least 6 leucine residues, optionally at least one cysteine residue, and at least two but no greater than three glutamic acids wherein the arginine residues are evenly distributed along the length of the peptide; and the peptide has a defined ratio of arginine to negatively charged amino acid residues and a defined ratio of hydrophilic amino acid residues to hydrophobic amino acid residues. The present invention is also directed to a nanoparticle and cell delivery system comprising the amphipathic cell penetrating peptide of the invention. The peptide, nanoparticle or cell delivery system of the invention may be used in therapy.
Type:
Grant
Filed:
August 28, 2017
Date of Patent:
January 29, 2019
Assignee:
The Queen's University of Belfast
Inventors:
Helen McCarthy, Aleksey Zholobenko, Ashley Davison, Tracy Robson
Abstract: A cell-penetrating peptide characterized in that it comprises an amino acid sequence consisting of XWXRLXXXXXX (SEQ ID No: 5), wherein X in position 1 is beta-A or S; X in positions 3, 9 and 10 are, independently from each other, W or F; X in position 6 is R if X in position 8 is S, and X in position 6 is S if X in position 8 is R; X in position 7 is L or none; X in position 11 is R or none, and wherein X in position 7 is L if X in position 11 is none.
Type:
Grant
Filed:
November 2, 2017
Date of Patent:
January 29, 2019
Assignee:
Aadigen, LLC
Inventors:
Gilles Divita, Sebastien Deshayes, Karidia Konate, May Catherine Morris
Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
Abstract: The present invention relates to the conjugation of Factor VII polypeptides with heparosan polymers. The resultant conjugates may be used to deliver Factor VII, for example in the treatment or prevention of bleeding disorders.
Type:
Grant
Filed:
March 8, 2017
Date of Patent:
January 15, 2019
Assignee:
Novo Nordisk Health Care AG
Inventors:
Carsten Behrens, Henrik Oestergaard, Henning Ralf Stennicke
Abstract: Disclosed herein is a personalized method for monitoring a condition or disorder associated with antibody production in a subject. The method can involve treating a biological sample comprising immunoglobulin from the subject to enzymatically cleave a target immunoglobulin associated with the PCD into one or more variable domain peptide fragments of the target immunoglobulin, and then measuring the one or more variable domain peptide fragments in the sample by quantitative mass spectrometry to quantify the amount of the target immunoglobulin in the sample.
Type:
Grant
Filed:
February 28, 2015
Date of Patent:
January 8, 2019
Assignee:
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Abstract: Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as malignancies and angiogenesis, and in neural disorders such as Alzheimer's disease. Stalk portions of the inhibitor molecules, and substrates of FAP and POP, are also disclosed and may be used, for example, in screening methods for identifying such inhibitors.
Type:
Grant
Filed:
May 23, 2017
Date of Patent:
December 18, 2018
Assignee:
The Board of Regents of the University of Oklahoma
Inventors:
Patrick A. McKee, Kenneth W. Jackson, Victoria J. Christiansen
Abstract: A composition comprising a first peptide selected from tripeptide, tetrapeptide and mixtures thereof; a second peptide selected from pentapeptide, hexapeptide, and mixtures thereof; an extract from the Laminaria genus, and whey protein, and a method for stimulating collagen synthesis in skin cells.
Abstract: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells, and combinations of T cell activating agents and/or an immune checkpoint inhibitors with and without peptides and peptidimimetics. The invention compounds and combinations can be used to inhibit cell growth, such as treat a tumor or cancer.
Abstract: The present disclosure provides novel macrocyclic compounds which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Type:
Grant
Filed:
March 1, 2017
Date of Patent:
December 4, 2018
Assignee:
Bristol-Myers Squibb Company
Inventors:
Martin Patrick Allen, Eric P. Gillis, David R. Langley, Michael Matthew Miller, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Katharine A. Grant-Young, Nicholas A. Meanwell, Paul Michael Scola
Abstract: Methods of treating obesity, metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes using a pentapeptide, LVKGRamide, derived from the C-terminus of Glucagon-Like Peptide 1 (GLP-1).
Abstract: The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit, as well as to kits for use in the same. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin comprises or consists of the following steps: (a) optionally providing a blood sample to be tested from an individual in need of treatment; (b) taking a single fasting blood (or plasma) glucose measurement from said individual in need of treatment; (c) using the single fasting blood (or plasma) glucose measurement to determine the insulin dose to be administered; and (d) administering the long-acting or ultra-long insulin to the individual at the dose determined in step (c).
Type:
Grant
Filed:
April 30, 2014
Date of Patent:
November 27, 2018
Assignee:
Novo Nordisk A/S
Inventors:
Thue Johansen, Ann Marie Ocampo Francisco, Torsten Christensen, Jens Harald Kongsoe, Trine Ahlgreen
Abstract: The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCR??-CD3??-CD3??-?? signaling complex. Yet more specifically, the peptides act on the TCR?/CD3??/?? signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions.
Abstract: The present invention deals with a bipodal-peptide binder that specifically binds with a target including (a) a structure stabilizing region that includes parallel, antiparallel or parallel and antiparallel amino acid strands wherein interstrand non-covalent bonds are formed; and (b) a target binding region I and a target binding region II that are bonded at both terminals of said structure stabilizing region and respectively include n and m amino acids, and a method of preparing same; the bipodal-peptide binder of the present invention exhibits the KD value (dissociation constant) of a very low level (for example, nM level) and, therefore, exhibits very high affinity toward a target. The bipodal-peptide binder of the present invention has applications not only in pharmaceuticals but also in in-vivo imaging, in vitro cell imaging, and drug delivery targeting, and can be very usefully employed as an escort molecule.
Type:
Grant
Filed:
October 20, 2009
Date of Patent:
November 20, 2018
Assignee:
GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventors:
Sang Yong Jon, Sung Hyun Kim, Se Ho Park
Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
Type:
Grant
Filed:
November 6, 2014
Date of Patent:
November 20, 2018
Assignee:
Zealand Pharma A/S
Inventors:
Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Ă˜sterlund, Kate Hansen, Lene Jessen
Abstract: Personal care compositions comprising a dipeptide and methods of using such compositions to treat the condition of keratinous tissue. The C terminal amino acid of said dipeptide is threonine. The personal care composition can be applied topically, ingested orally, injected, or used as part of a combined treatment regimen.
Abstract: Methods are provided for quantifying the Androgen receptor protein (AR) protein directly in biological samples that have been fixed in formalin, using Selected Reaction Monitoring (SRM)/Multiple Reaction Monitoring (MRM) mass spectrometry. The biological samples are chemically preserved and fixed and can be, for example, tissues treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks. A protein sample is prepared from said biological sample using, for example, the Liquid Tissue protocol and the AR protein is quantitated in the Liquid Tissue sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described.
Type:
Grant
Filed:
April 30, 2015
Date of Patent:
November 13, 2018
Assignee:
Expression Pathology, Inc.
Inventors:
David B. Krizman, Todd Hembrough, Sheeno Thyparambil, Eunkyung An